Weight Regain After Stopping Incretin / GLP-1 Therapy

Important disclaimers (please read first)

1. This is education only. It is not medical advice, not a diagnosis, and not a treatment plan for you.
2. We are not saying you are a candidate. Nothing here confirms that you are (or are not) a fit for any medicine or program. At Regen Therapy MD, a physician decides only after a proper consult.
3. Results vary. Trial averages describe study populations. They are not promises for any individual. Nothing on this page promises weight loss, weight maintenance, or any outcome.
4. Brand FDA-approved products are not the same as compounded versions. An FDA-approved brand medicine and a compounded formulation are not equivalent or interchangeable.
5. Compounded drugs are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed.
6. No dosing or protocols. This page does not give doses, titration schedules, stacking plans, or “how to stop” instructions.
7. Licensure and shipping. Any telehealth or shipping, if offered, applies only where we are licensed. This page does not claim nationwide service.
8. How Regen frames next steps. A discovery call is a non-clinical chat to help you learn what you may be a candidate for—never that you are one.
9. Claims and sources. No made-up testimonials. Percentages and other numbers below are quoted only as published in the cited peer-reviewed papers (with PMIDs) or FDA pages.

Why people ask about “what happens when I stop”

Incretin-based medicines—including certain FDA-approved glucagon-like peptide-1 (GLP-1) receptor agonists and related dual agonists—have changed how clinicians talk about chronic weight management. A common follow-up question is honest and important:

What does published evidence say about weight after treatment is stopped?

The short answer from large withdrawal and extension studies: many participants regain a substantial portion of the weight they lost, and some cardiometabolic improvements move back toward baseline. That pattern does not mean every person will regain the same amount. Individual results vary. No blog can predict your course.

What the STEP 1 extension found (semaglutide withdrawal)

The STEP 1 trial extension (Wilding et al., Diabetes, Obesity and Metabolism, 2022; PMID 35441470) followed a representative subset of adults who had completed 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg or placebo (plus lifestyle intervention), then discontinued treatments—including lifestyle intervention—and were assessed for a further year off treatment.

Published extension results included:

• Extension analyses included 327 participants.
• From week 0 to week 68, mean weight loss was 17.3% (SD 9.3%) with semaglutide and 2.0% (SD 6.1%) with placebo.
• Following treatment withdrawal, semaglutide participants regained 11.6 (SD 7.7) percentage points of lost weight by week 120 (placebo: 1.9 percentage points, SD 4.8).
• Net mean loss from week 0 to week 120 was 5.6% (SD 8.9%) in the semaglutide arm versus 0.1% (SD 5.8%) with placebo.
• The authors concluded that one year after withdrawal, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic variables, and that findings support the chronicity of obesity.

Those figures are group means from that extension population. They are not a promise of your personal result.

What STEP 4 showed (continue vs switch to placebo)

STEP 4 (Rubino et al., JAMA, 2021; PMID 33755728) used a different design: after a 20-week run-in on semaglutide (mean weight loss of 10.6% among those randomized), participants who reached the maintenance dose were randomized to continued weekly semaglutide or switch to placebo, with lifestyle intervention in both groups, through week 68.

Published primary findings included:

• From week 20 to week 68, mean body weight change was −7.9% with continued semaglutide versus +6.9% after switch to placebo (difference −14.8 percentage points; 95% CI −16.0 to −13.5).

Again: trial averages in a defined study population—not a promise for any reader.

What SURMOUNT-4 found (tirzepatide withdrawal)

SURMOUNT-4 (Aronne et al., JAMA, 2024; PMID 38078870) studied continued tirzepatide versus switch to placebo after an open-label lead-in.

Published findings included:

• Participants who completed the 36-week lead-in experienced a mean weight reduction of 20.9%.
• Mean percent weight change from week 36 to week 88 was −5.5% with continued tirzepatide versus +14.0% with placebo (difference −19.4%; 95% CI −21.2% to −17.7%).
• 89.5% of participants continuing tirzepatide at week 88 maintained at least 80% of lead-in weight loss, versus 16.6% receiving placebo.
• Overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo.
• Authors stated that withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction.

Tirzepatide is a dual GIP/GLP-1 agonist (not a GLP-1-only agent). It is included here because it is part of the broader incretin withdrawal literature patients often ask about.

What systematic reviews add (pooled patterns, still not your forecast)

Peer-reviewed syntheses report similar directional patterns:

1. Berg et al., Obesity Reviews, 2025 (PMID 40186344) — After discontinuing GLP-1RA therapy across 8 RCTs (2372 participants), pooled mean weight regain was 2.20 kg (95% CI 1.69–2.70) for liraglutide cohorts and 9.69 kg (95% CI 5.78–13.60) for semaglutide/tirzepatide cohorts. Authors noted regain was proportional to original weight loss and that discontinuation should be discussed when stopping therapy.

2. West et al., BMJ systematic review/meta-analysis, 2026 (PMID 41500720) — Across 37 studies (9341 participants) of weight-management medications, average monthly weight regain after cessation was 0.4 kg (95% CI 0.3–0.5). Cardiometabolic markers were projected to return to baseline within 1.4 years after cessation in that analysis. Regain after medication was faster than after behavioural weight-management programmes (by 0.3 kg monthly in the comparison reported).

3. Trajectory meta-regression, EClinicalMedicine, 2026 (PMID 41938838) — In a nonlinear meta-regression of six RCTs (3236 participants), authors reported that at 1 year post-cessation, 60% of the weight lost during treatment was regained; extrapolated plateau was estimated at 75.3% (95% CI 68.9–81.6) of weight lost on treatment. Extrapolations beyond observed follow-up are model-based and are not individual predictions.

Meta-analyses pool heterogeneous trials. They strengthen the pattern (“regain after stopping is common in published evidence”) without converting averages into promises.

How to read these numbers without overclaiming

What this page does not do

• It does not tell you to start, continue, taper, or stop any medicine.
• It does not give doses or “how to come off” schedules.
• It does not claim Regen Therapy MD results match STEP, SURMOUNT, or meta-analysis averages.
• It does not equate brand FDA-approved products with compounded or research-labeled products.

FDA has separately warned about unapproved GLP-1 products used for weight loss, including compounded versions (which are not FDA-approved) and products falsely labeled “for research purposes” or “not for human consumption.” See FDA’s consumer-facing statement linked in Sources.

Questions worth bringing to a clinician visit

Use these as conversation starters—not as a script that implies you will be treated:

1. If I respond to an approved therapy, what does maintenance planning look like in my case?
2. What happens to weight and labs in published withdrawal studies—and how does that inform my risk discussion?
3. If I need to stop, what monitoring and lifestyle supports make sense for me?
4. Is the product under discussion an FDA-approved finished drug, a compounded preparation, or something else?
5. What side effects, contraindications, and label warnings apply to my history?

FAQ

Do most people regain weight after stopping GLP-1 or related incretin therapy?

Published withdrawal and extension trials—including STEP 1 extension (PMID 35441470), STEP 4 (PMID 33755728), and SURMOUNT-4 (PMID 38078870)—report substantial mean regain after stopping or switching to placebo in those study populations. Systematic reviews report similar directional patterns. Individual results vary; none of this promises your outcome.

Does “two-thirds regain” apply to everyone?

No. The STEP 1 extension authors stated participants regained two-thirds of prior weight loss as a group finding one year after withdrawal in that extension. It is not a personal prediction.

If weight comes back, did the medicine “fail”?

Not necessarily. Several papers frame obesity as a chronic condition where benefits may depend on ongoing therapy for appropriate patients. That is a clinical framing from the literature—not a claim that everyone must stay on medicine forever.

Are compounded GLP-1 products the same as brand FDA-approved drugs?

No. FDA states compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. Brand FDA-approved products and compounded formulations are not equivalent.

How do I talk with Regen Therapy MD?

Book online, use Contact Us, call (424) 349-6008, or email book@regentherapymd.com. A discovery call is non-clinical and explores what you may be a candidate for.

Talk with Regen Therapy MD

If you want a physician-directed conversation about metabolic options—and an honest discussion of what published evidence says about maintenance and discontinuation—start with booking, not with a self-selected online product:

• Book: https://book.mypatientnow.com/practice/TqZLiT
• Contact: https://www.regentherapymd.com/contact-us
• Phone: (424) 349-6008
• Email: book@regentherapymd.com

Clinic: Beverly Hills — 8920 Wilshire Blvd, Suite 604

Disclaimers (footer)

Educational content only — not medical advice, diagnosis, or a treatment plan. Does not confirm candidacy. Individual results vary; no outcome promises. Percentages and kg figures above are quoted from the cited peer-reviewed publications only. FDA-approved brand products and compounded formulations are not equivalent. Compounded drugs are not FDA-approved. No dosing or stop/start protocols. Telehealth/shipping only where licensed; no nationwide-service claim. Discovery call = non-clinical / may-be-candidate framing. No fabricated testimonials.

Sources

1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID 35441470 · PMC9542252.
2. Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance… STEP 4. JAMA. 2021;325(14):1414-1425. PMID 33755728.
3. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction… SURMOUNT-4. JAMA. 2024;331(1):38-48. PMID 38078870 · PMC10714284.
4. Berg S, et al. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis. Obes Rev. 2025;26:e13929. PMID 40186344.
5. West S, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. PMID 41500720.
6. Trajectory of weight regain after cessation of GLP-1 receptor agonists… EClinicalMedicine. 2026;103796. PMID 41938838.
7. U.S. FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.